Lumida
/JYNT
⌘K
Joint Corp

Joint Corp

JYNT
$8.91USD↓-1.22%-0.11 today

MARKET CAP

127.0M

P/E (TTM)

82.9x

FWD P/E

31.4x

DAY RANGE

$9 – $9

52W RANGE

$8
$12

AI Summary

Stalk
Buy NowMedium

JYNT is in Stage 2 advancing, having built a clear higher‐highs/higher‐lows sequence off its May lows and trading above rising 9/21/50 EMAs on expanding volume. Active Lockout Rally and HH/HL patterns reinforce bullish continuation, while short‐term pullbacks into the EMAs are supported. Despite overbought signals and a declining 200 DMA overhead, timing conditions favor immediate participation to ride further upside momentum.

  • ↑Joint 2.0 franchising rollout on track for year-end completion.
  • ↑Franchise licenses sold rose to 13 in Q1 2026 versus 7 a year ago.
  • ↓Comparable store sales declined 4.2%, highlighting patient acquisition challenges.
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

The Joint Corp (NASDAQ: JYNT) is a leading franchisor in the chiropractic care sector that operates a network of chiropractic clinics across the United States. The company emphasizes accessibility and affordability in its health services, providing holistic pain relief solutions. As part of its strategic initiative, The Joint is undergoing a transformation to become a pure-play franchisor by refranchising corporate-owned clinics. This transition is aimed not only at optimizing its operational efficiency but also enhancing profitability through a focus on patient engagement and targeted marketing.

Bull says

  • ↑Joint 2.0 franchising rollout on track for year-end completion.
  • ↑Franchise licenses sold rose to 13 in Q1 2026 versus 7 a year ago.
  • ↑Q1 2026 revenue grew 5% YoY to $13.3 M, driven by franchise fees.
  • ↑Completed $9 M share repurchases in Q4 2025 to enhance shareholder value.
  • ↑Strong earnings revisions and institutional interest underpin upside potential.
  • ↑Low leverage provides balance-sheet flexibility amid economic headwinds.

Bear says

  • ↓Comparable store sales declined 4.2%, highlighting patient acquisition challenges.
  • ↓Adjusted EBITDA fell to $46 K in Q1 2026 from $425 K a year earlier.
  • ↓Rising operational costs and consumer price sensitivity squeeze margins.
  • ↓High economic sensitivity could magnify performance volatility in downturns.
  • ↓Weak growth outlook and negative profitability factors signal subdued returns.
  • ↓Elevated volatility and competitive risks may deter risk-averse investors.

Earnings Call · Q1 2025 · Mgmt. Guidance

Updated 05-30-2026neutral

Transcript signals

Bull points

  • System-wide sales were $132.6 million, up 5%, demonstrating resilience in this economic environment.
  • Revenue from continuing operations increased 7%.
  • We will initiate dynamic revenue management, strengthen our digital marketing and promotional calendar, and upgrade our patient-facing technology.

Bear points

  • Adjusted EBITDA from continuing operations was $46,000 compared to $425,000 in quarter one, 2024.
  • labor costs have increased significantly, squeezing clinic-level margins.
  • Comp sales for mature clinics open 48 months were negative 2%.
Read full transcript analysis ›